Clinical Trial Update: Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia [Phase 1, Phase 2]

View source ↗

Summary

This phase 1/2 trial evaluates gallium-68 DOTATATE PET imaging to localize phosphaturic mesenchymal tumors causing tumor-induced osteomalacia, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomalacia
• Tumor-induced Osteomalacia

Drugs mentioned

• Ga-DOTATATE (gallium-68 DOTATATE)

Snippet

Sponsor: Mayo Clinic | Conditions: Osteomalacia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-04-30